![]() | |
Names | |
---|---|
IUPAC name 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]imidazol-4-yl]phenoxy]-N,N-diethylpropan-1-amine | |
Identifiers | |
3D model (JSmol) | |
ChEMBL | |
ChemSpider | |
DrugBank | |
EC Number |
|
KEGG | |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
| |
| |
Properties | |
C32H38ClN3O2 | |
Molar mass | 532.13 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Azeliragon (TTP488 or PF-04494700) is a small-molecule RAGE inhibitor. It is developed by vTv Therapeutics for various cancers, including triple-negative breast cancer [1] [2] and pancreatic cancer. [3]
The chemical reached Phase III trials in slowing cognitive deterioration in early stage Alzheimer's disease patients. [4] [5] [6] It was also tested in people with diabetic neuropathy [7] and animal models of graft-vs-host disease. [8]